Literature DB >> 6268957

Use of the enzyme-linked immunosorbent assay (ELISA) for the estimation of serum antibodies in an influenza virus vaccine study.

R Jennings, T Smith, C W Potter.   

Abstract

The value of the enzyme-linked immunosorbent assay (ELISA) for determining the serum antibody responses of volunteers following immunisation with various inactivated influenza virus vaccines was assessed, and the incidence of seroconversions, as measured by both haemagglutination-inhibition (HI) and ELISA response of the volunteers determined. ELISA was found to be more sensitive than the HI test in detecting serum antibodies, but was also less specific under the conditions used. With regard to efficacy, the whole virus vaccine proved to be more effective in inducing serum antibody in an unprimed population than either tween-ether split or subunit adsorbed vaccines, but the reverse situation held when the population was primed with respect to the antigen concerned.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268957     DOI: 10.1007/bf02125524

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  28 in total

1.  Sensitivity of enzyme-linked immunosorbent assay, complement fixation, and hemagglutination inhibition serological tests for detection of Sendai virus antibody in laboratory mice.

Authors:  J C Parker; A J O'Beirne; M J Collins
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

2.  Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic.

Authors:  G MEIKLEJOHN; C H KEMPE; W G THALMAN; E H LENNETTE
Journal:  Am J Hyg       Date:  1952-01

3.  Evaluation of enzyme-linked immunosorbent assay (ELISA) for mumps virus antibodies.

Authors:  P O Leinikki; I Shekarchi; N Tzan; D L Madden; J L Sever
Journal:  Proc Soc Exp Biol Med       Date:  1979-03

4.  Influenzavirus neuraminidase and neuraminidase-inhibition test procedures.

Authors:  M Aymard-Henry; M T Coleman; W R Dowdle; W G Laver; G C Schild; R G Webster
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

5.  Neutralization test in influenza: use in individuals without hemagglutination inhibition antibody.

Authors:  P A Gross; A E Davis
Journal:  J Clin Microbiol       Date:  1979-09       Impact factor: 5.948

6.  Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza.

Authors:  G C Schild; M S Pereira; P Chakraverty
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

7.  Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection.

Authors:  L S Richardson; R H Yolken; R B Belshe; E Camargo; H W Kim; R M Chanock
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

8.  Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain.

Authors:  B R Murphy; H P Holley; E J Berquist; M M Levine; S B Spring; H F Maassab; A P Kendal; R M Chanock
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

9.  A microplate immunoenzyme assay for anti-influenza antibodies.

Authors:  C Lambre; K N Kasturi
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

10.  Reactogenicity and immunogenicity of whole and ether-Tween-split influenza A virus vaccines in volunteers.

Authors:  R Jennings; A Clark; J S Oxford; D J Hockley; C W Potter
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

View more
  8 in total

1.  The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus.

Authors:  E T Ben Ahmeida; R Jennings; M Erturk; C W Potter
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Use of single radial haemolysis for assessing antibody response to influenza virus vaccines in animals.

Authors:  T L Smith; R Jennings; C W Potter
Journal:  Med Microbiol Immunol       Date:  1987       Impact factor: 3.402

3.  The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.

Authors:  K F Hu; M Elvander; M Merza; L Akerblom; A Brandenburg; B Morein
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

4.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

5.  Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature.

Authors:  W E Beyer; A M Palache; A D Osterhaus
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 6.  Influenza diagnosis and vaccination in Poland.

Authors:  L B Brydak; A Wozniak-Kosek; A Nitsch-Osuch
Journal:  Respir Physiol Neurobiol       Date:  2013-02-16       Impact factor: 1.931

7.  Comparison of hemagglutination inhibition, single radial hemolysis, virus neutralization assays, and ELISA to detect antibody levels against seasonal influenza viruses.

Authors:  Claudia Maria Trombetta; Edmond J Remarque; Daniella Mortier; Emanuele Montomoli
Journal:  Influenza Other Respir Viruses       Date:  2018-08-11       Impact factor: 4.380

8.  Detection of anti-NS1 antibodies after pandemic influenza exposure: Evaluation of a serological method for distinguishing H1N1pdm09 infected from vaccinated cases.

Authors:  Anna Hayman Robertson; Milada Mahic; Miloje Savic; Gro Tunheim; Olav Hungnes; Lill Trogstad; Walter Ian Lipkin; Siri Mjaaland
Journal:  Influenza Other Respir Viruses       Date:  2020-01-19       Impact factor: 4.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.